Table 2.
Baseline characteristics of the patients
| Features | Total (n) | P53,n(%) | PGP9.5,n(%) | SOX2,n(%) | GAGE7,n(%) | GBU4-5,n(%) | MAGE A1,n(%) | CAGE, n(%) |
|---|---|---|---|---|---|---|---|---|
| Age (years) | 509 | |||||||
| ≥ 60 | 265 | 4(1.5) | 11(4.2) | 23(8.7) | 15(5.7) | 35(13.2) | 10(3.8) | 6(2.3) |
| <60 | 244 | 0(0) | 1(0.4) | 10(4.1) | 9(3.7) | 10(4.1) | 3(1.2) | 6(2.5) |
| Sex | ||||||||
| Male | 227 | 4(1.8) | 8(3.5) | 23(10.1) | 8(3.5) | 17(7.5) | 12(5.3) | 2(0.9) |
| Female | 282 | 0(0) | 4(1.4) | 10(3.5) | 16(5.7) | 28(9.9) | 1(0.4) | 10(3.5) |
| Smoking history | ||||||||
| Yes | 113 | 2(1.8) | 3(2.7) | 16(14.2) | 6(5.3) | 11(9.7) | 8(7.1) | 1(0.9) |
| No | 396 | 2(0.5) | 9(2.3) | 17(4.3) | 18(4.5) | 34(8.6) | 5(1.3) | 11(2.8) |
| Pathological type | ||||||||
| Benign | 76 | 0(0) | 1(1.3) | 2(2.6) | 0(0) | 3(3.9) | 0(0) | 0(0) |
| Malignant | 433 | 4(0.9) | 11(2.5) | 31(7.2) | 24(5.5) | 42(9.7) | 13(3.0) | 12(2.8) |
| Precancerous | 18 | 0(0) | 0(0) | 1(5.6) | 1(5.6) | 2(11.1) | 0(0) | 1(5.6) |
| Adenocarcinoma | 344 | 2(0.6) | 5(1.5) | 17(4.9) | 18(5.2) | 28(8.1) | 4(1.2) | 10(2.9) |
| Squamous | 44 | 1(2.3) | 4(9.1) | 8(18.2) | 4(9.1) | 8(18.2) | 8(18.2) | 0(0) |
| SCLC | 11 | 1(9.1) | 0(0) | 2(18.2) | 1(9.1) | 1(9.1) | 0(0) | 0(0) |
| Other pathological types | 9 | 0(0) | 1(11.1) | 1(11.1) | 0(0) | 2(22.2) | 0(0) | 0(0) |
| Poorly differentiated | 7 | 0(0) | 1(14.3) | 2(28.6) | 0(0) | 1(14.3) | 1(14.3) | 1(14.3) |
| Clinical stage | ||||||||
| I | 277 | 0(0) | 3(1.1) | 11(4.0) | 15(5.4) | 23(8.3) | 1(0.4) | 6(2.2) |
| II | 13 | 0(0) | 1(7.7) | 0(0) | 1(7.7) | 0(0) | 2(15.4) | 0(0) |
| III | 53 | 3(5.7) | 4(7.5) | 10(18.9) | 4(7.5) | 10(18.9) | 8(15.1) | 1(1.9) |
| IV | 29 | 0(0) | 1(3.4) | 8(27.6) | 2(6.9) | 1(3.4) | 2(6.9) | 2(6.9) |